Phaseline

Targets › CD1D

CD1D (Antigen-presenting glycoprotein CD1d): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Apr 2028.

Antigen-presenting protein that binds self and non-self glycolipids and presents them to T-cell receptors on natural killer T-cells. (UniProt, P15813)

Open in Phaseline: the race on CD1D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioPhoenixBPC-2001
Invariant natural killer T (iNKT) cell activator
CD1DPhase 2Graft -Versus-host-diseaseApr 2028

Conditions

Graft -Versus-host-disease (1)

Modalities

small molecule (1)

Companies

BioPhoenix (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.